| Identification | Back Directory | [Name]
2-[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]ACETIC ACID | [CAS]
17969-20-9 | [Synonyms]
mialex
8L-323S
Fenclozic
ici54,450
fenclozicacid
acidofenclozico
acidumfenclozicum
Acide p-chlorophenyl-2
2-(4-chlorophenyl)-4-thiazoleaceticaci
2-(p-chlorophenyl)-4-thiazoleaceticaci
2-(4-chlorophenyl)-4-thiazoleaceticacid
2-(p-chlorophenyl)-4-thiazole-aceticacid
2-(p-chlorophenyl)thiazol-4-ylaceticacid
acidep-chlorophenyl-2thiazole-acetique-4
2-(4-chlorophenyl)-thiazol-4-ylaceticacid
4-Thiazoleacetic acid, 2-(4-chlorophenyl)-
4-THIAZOLEACETIC ACID, 2-(p-CHLOROPHENYL)-
2-[2-(4-chlorophenyl)-4-thiazolyl]acetic acid
2-[2-(4-chlorophenyl)thiazol-4-yl]acetic acid
[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]ACETIC ACID
4-Thiazoleacetic acid, 2-(4-chlorophenyl)- (9CI)
2-[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]ACETIC ACID
2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethanoic acid | [Molecular Formula]
C11H8ClNO2S | [MDL Number]
MFCD00721754 | [MOL File]
17969-20-9.mol | [Molecular Weight]
253.7 |
| Chemical Properties | Back Directory | [Melting point ]
150-152°C | [Boiling point ]
145°C (rough estimate) | [density ]
1.2270 (rough estimate) | [refractive index ]
1.6300 (estimate) | [storage temp. ]
2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
3.83±0.10(Predicted) | [color ]
Off-White to Pale Brown | [InChI]
1S/C11H8ClNO2S/c12-8-3-1-7(2-4-8)11-13-9(6-16-11)5-10(14)15/h1-4,6H,5H2,(H,14,15) | [InChIKey]
APBSKHYXXKHJFK-UHFFFAOYSA-N | [SMILES]
OC(=O)Cc1csc(n1)-c2ccc(Cl)cc2 |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
22 | [WGK Germany ]
WGK 3 | [HazardClass ]
IRRITANT | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral | [Toxicity]
LD50 in rats, mice (mg/kg): 850, 1000 orally; 250, 300 i.v. (Hepworth) |
| Hazard Information | Back Directory | [Originator]
Fenclozic Acid,ZYF Pharm Chemical | [Uses]
Fenclozic Acid is a a potent antiinflammatory agent with analgesic and antipyretic properties and is a human hepatotoxic drug. | [Manufacturing Process]
3.7 parts of 2-(4-chlorophenyl)-4-cyanomethylthiazole and 35 parts of 6 N
hydrochloric acid are heated under reflux for 2 hours. The solution is cooled
by the addition of ice and made alkaline to pH 8 by the addition of 30%
aqueous ammonia. The mixture is filtered to remove trace impurities, and an
excess of 40% sodium hydroxide solution is then added to the filtrate to cause
precipitation of a sodium salt, which is collected by filtration and crystallised
from water. There is thus obtained sodium 2-(4-chlorophenyl)thiazol-4-
ylacetate, M.P. 13°C (decomposition).
This sodium salt is dissolved in hot water, and the solution is brought to pH 4
by the addition of acetic acid, which causes the precipitation of 2-(4-
chlorophenyl)thiazol-4-ylacetic acid. This is collected by filtration, washed with
water, and dried in vacuo over phosphorus pentoxide. It has an M.P. 155-
156°C (from ethyl acetate). | [Therapeutic Function]
Antiinflammatory, Analgesic, Antipyretic |
|
|